Solasia Pharma Adjusts Revenue Recognition Timing for Sancuso Sales

TOKYO, Jul 02 (Pulse News Wire) – Solasia Pharma K.K. (4597.T) announced that revenue recognition for sales of its Sancuso product to MAAB Co., a new Chinese distribution partner, will be delayed until the third quarter of fiscal 2026 due to ongoing documentation procedures related to the partnership change.

The company had previously forecasted half of the total expected annual revenue of ¥420 million would come from Sancuso sales, which were completed and payments received during the second quarter. However, the delay does not impact the company's overall performance outlook for the fiscal year ending March 2026. In February, Solasia Pharma disclosed an estimated annual revenue target of ¥420 million from the sale of Sancuso, Darvias, and Episil products. The company noted that approximately half of this estimate was anticipated to stem from Sancuso sales to MAAB Co.

Despite completing shipments and receiving payment in U.S. dollars equivalent to USD1,299,240 during the second quarter, the necessary documentation adjustments are still pending, necessitating a shift in revenue reporting to the third quarter. The adjustment in revenue timing reflects the complexities associated with transitioning to a new distributor and underscores the importance of thorough administrative processes in international pharmaceutical transactions. Solasia Pharma emphasized that while there is no immediate impact on their projected financial results for the fiscal year ending March 2026, uncertainties such as economic conditions, exchange rate fluctuations, and competitive dynamics could influence future outcomes.